Status:
UNKNOWN
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Triple Negative Breast Cancer
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to compare the 3-year disease-free survival of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for t...
Detailed Description
Triple-negative breast cancer (TNBC) lack the expression of oestrogen receptor (ER), progesterone receptor(PR) and human epidermal growth factor receptor 2 (HER2) , and characterizes an aggressive beh...
Eligibility Criteria
Inclusion
- 18-60 years
- Histologically confirmed adenocarcinoma of the breast, complete tumor removal by either modified radical mastectomy or local excision plus axillary lymph node dissection (i.e., breast conservation therapy) or sentinel node biopsy. (Tumor-free margins at least 1 mm for both invasive and noninvasive carcinoma except for lobular carcinoma in situ (less than 1 mm allowed);
- Histologically confirmed ER(-) PR(-) and HER-2(IHC(immunohistochemistry) 0-1+ or FISH (fluorescence in situ hybridization) negative)
- Next-generation sequencing confirmed homologous recombination repair deficiency
- Meet one of the following criteria:
- (1) Positive axillary lymph nodes; (2) Negative axillary lymph nodes with at least one of the following risk factors: age\<= 35 years; grade III; infiltrative tumor size \> 2cm; intravascular tumor embolus; Ki-67\>=50%.
- 6\. Eastern Cooperative Oncology Group (ECOG) Performance Score 0-1 7. Adequate bone marrow reserve with ANC \> 1500, HGB \> 9g/dL and platelets \> 100,000.
- 8\. Adequate renal function with serum creatinine \< 2.0. 9. Adequate hepatic reserve with serum bilirubin \< 2.0, AST/ALT \< 2X the upper limit of normal, and alkaline phosphatase \< 5X the upper limit of normal. Serum bilirubin \> 2.0 is acceptable in the setting of known Gilbert's syndrome.
- 10\. Not pregnant, and on appropriate birth control if of child-bearing potential.
- 11\. Written informed consent according to the local ethics committee requirements.
Exclusion
- Prior systemic treatment of breast cancer, including chemotherapy;
- Metastatic breast cancer;
- Patients with medical conditions that indicate intolerant to adjuvant therapy and related treatment, including uncontrolled pulmonary disease, diabetes mellitus, severe infection, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease;
- Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive;
- Contraindication for using dexamethasone;
- History of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP\>180 mmHg or diastolic BP\>100 mmHg);
- Pregnant or breast feeding.
- Hepatic, renal, or bone marrow dysfunction as detailed above.
- Known severe hypersensitivity to any drugs in this study;
- Treatment with any investigational drugs within 30 days before the beginning of study treatment.
Key Trial Info
Start Date :
February 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03876886
Start Date
February 22 2019
End Date
December 1 2024
Last Update
March 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China, 100021